APA (7th ed.) Citation

van Mourik, N., van Amstel, R. B. E., Slim, M. A., van Vught, L. A., van der Poll, T., Huckriede, J., . . . Müller, M. C. A. (2025). A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients. Intensive care medicine experimental, 13(1), 84-15. https://doi.org/10.1186/s40635-025-00790-4

Chicago Style (17th ed.) Citation

van Mourik, Niels, et al. "A Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered Low-anticoagulant Heparin (M6229) in Critically Ill Sepsis Patients." Intensive Care Medicine Experimental 13, no. 1 (2025): 84-15. https://doi.org/10.1186/s40635-025-00790-4.

MLA (9th ed.) Citation

van Mourik, Niels, et al. "A Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered Low-anticoagulant Heparin (M6229) in Critically Ill Sepsis Patients." Intensive Care Medicine Experimental, vol. 13, no. 1, 2025, pp. 84-15, https://doi.org/10.1186/s40635-025-00790-4.